ClinicalTrials.gg
CompletedNCT03469713NIVESUpdated May 3, 2022

Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of Nivolumab in Renal Cancer Metastatic, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Gruppo Oncologico Italiano di Ricerca Clinica · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing nivolumab in Kidney Neoplasms — 4 open to participants now, 7 under way, 2 of them phase 3. Nivolumab · Kidney Neoplasms.

Enrollment
9th of 19
69 · median 50
Started
2017
with 4 others
Phase 2
7 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
1 of 19
Gruppo Oncologico Italiano di Ricerca Clinica

Among the 19 studies testing nivolumab in Kidney Neoplasms, this one is the 9th largest by enrollment, is one of 5 that started in 2017, is one of 7 in phase 2, and was the 8th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 209 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

4 of the 19 studies testing nivolumab in Kidney Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 172 Kidney Neoplasms studies recruiting now, 132 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nivolumab in Kidney Neoplasms, or all of them as a file.
02

Study summary

NIVES study is an ongoing phase II, single arm, multicenter study. In this trial pts received SBRT to one non-brain measurable lesion and concomitant NIVOLUMAB, an anti-programmed cell death (PD-1). Combining SBRT with NIVO may enhance the antitumor immune responses and improve clinical outcomes, how it was demonstrated for other solid tumors with a phenomenon known as the abscopal effect . It was planned to enrolled a total of 68 pts within 12 months. The objective of the current analysis is to describe the first report of safety profile of NIVO in combination with SBRT.

03

Conditions studied

  • Renal Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years on day of signing
  • Performance status of 0, 1 on the Performance Scale
  • confirmed RCC not suitable for curative-intent local therapy
  • Disease progressed after ≤ 2 prior anti-angiogenic therapies
  • > 12 weeks
  • 2 or more measurable non-brain sites of disease based on 1.1, whose at least one potentially suitable for treatment with SBRT. In the case of a non measurable bone lesion suitable for treatment with SBRT, even only one measurable non-brain site of disease is allowed
  • Patients are eligible if are treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 14 days prior to enrollment. In addition, patients must either be off or on a stable dose or decreasing dose of ≤ 10 mg daily prednisone (or equivalent)
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with an agent directed at , PD-L1, or PD-L2
  • Currently participating in or has participated in a study of an agent or using an investigational device within 2 weeks of the first dose of treatment
  • Any active or recent history of a known or suspected disease or recent history of a syndrome that required systemic (> 10 mg daily prednisone equivalent) or medications except for syndromes which would not be expected to recur in the absence of an external trigger
  • Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Active brain (CNS) and/or carcinomatous meningitis
  • Prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
  • Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment
  • Any positive test for or virus indicating acute or chronic infection
  • Additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
  • Evidence of interstitial lung disease, active non-infectious pneumonitis, or a history of grade 3 or greater pneumonitis
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
  • within 30 days prior to the first dose of trial treatment
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Nivolumab

    Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity . SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab).

    Drug: Nivolumab

Interventions

  • Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity . SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab).

06

What researchers measure

Primary outcomes

  1. ORR Objective Response Rate

    Objective Response Rate (ORR) , as determined by investigator assessment per RECIST 1.1 Secondary as determined by investigator assessment per RECIST 1.1

    Time frame: 36 months from the first administration of nivolumab

Secondary outcomes

  1. PFS Progression Free Survival

    the time between the date of registration and the first date of documented progression, based on invesigator assessment (as per RECIST 1.1 criteria), or death due to any cause, whichever occurs first

    Time frame: 36 months from the first administration of nivolumab

  2. OS Overall Survival

    the time from registration to the date of death from any cause

    Time frame: 36 months from the first administration of nivolumab

  3. ORR (Objective Response Rate) of irradiated and non-irradiated metastases and duration of response

    determined by investigator assessment per RECIST 1.1

    Time frame: 36 months from the first administration of nivolumab

  4. Incidence, nature and severity of Adverse Event (safety and tolerability)

    All Adverse Events (AEs) and laboratory abnormalities will be collected and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03

    Time frame: 36 months from the first administration of nivolumab

Other outcomes

  1. Analysis of expression of PD-L1

    Immune checkpoint inhibitors act by shortcutting the communication between immune cells and tumor cells mediated by the PD1-PDL1 interaction. Discordant results about the correlation of PDL1 expression and response to immunotherapy exist. Thus, we will investigate the expression of PDL1 in the tumor using four available IHC test (Dako 28.8, Dako 22C3, Ventana SP142, Ventana SP 263) and we will correlate levels of expression with response to treatment.

    Time frame: 36 months from the first administration of nivolumab

  2. Analysis of the genetic background of the tumor and its impact on the response to therapy

    To evaluate whether and how the initial genetic background of the renal carcinoma may impact on response to treatment in the present setting a deep sequencing analysis will be performed to assess mutational status of 578 cancer genes using the Comprehensive Cancer Design panel (Roche) and MySeq Illumina Next Generation Sequencer. The overall mutations load and the type of mutations detected will be correlated with the response to treatment.

    Time frame: 36 months from the first administration of nivolumab

  3. Analysis of the immuno-modulation during therapy.

    To investigate the effect of stereotactic radiotherapy on the modulation of the immune system we propose to analyze variation in the plasma levels of soluble immune-modulators during treatment. Will be use the Bio-Plex Pro™ Human Inflammation Assay (Bioplex, Biorad) that enables to detect and quantify a panel of 24 key biomarkers of inflammation including TNF superfamily proteins, IFN family proteins, and Treg cytokines

    Time frame: 36 months from the first administration of nivolumab

  4. Identification of somatic mutations associated with acquired resistance to checkpoint inhibitors

    we will investigate JAK1, JAK2 and B2M mutations by in the circulating free tumor DNA (ctDNA) obtained from the plasma samples. The ctDNA will be analyzed with a multiplexed sequencing assay that generates reads containing targeted regions along with a molecular tag that allows the accompanying optimized variant analysis software to assemble the reads into families of molecules originating from the same initial ctDNA molecules and model errors accumulated during library amplification, templating, and sequencing to accurately reconstruct the sequence of the original ctDNA molecule. The resulting sequence is then used to make variant calls down to 0.05% allele ratio with high sensitivity and specificity.

    Time frame: 36 months from the first administration of nivolumab

07

Study locations

1 site
  • Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova
    Reggio Emilia, 42123, Italy
08

References and documents

Publications

  • Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17. PubMed 32203306 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2019, 19 months.

Of 64 non-industry phase 2 interventional studies under Kidney Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 112. This study's 19 months is below that.

Counting every sponsor, half of 74 studies reached it within 67 months; a quarter within 36 and three quarters within 112.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Mar 19, 2018
StartActual
Jul 14, 2017
Primary completionActual
Mar 4, 2019
CompletionActual
Jul 14, 2021
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03469713
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Responsible party
Sponsor
First posted
Mar 19, 2018
Start date
Jul 14, 2017
Primary completion
Mar 4, 2019
Completion
Jul 14, 2021
Last update
May 3, 2022

Study contacts

Carmine Pinto, MD
principal investigator · Gruppo Oncologico Italiano di Ricerca Clinica

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion